-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lipoprotein E (ApoE) is an important lipid transporter protein in the brain.
its synthesis is controlled by three allied genes on the two gene bits of the encoded gene APOE 4th exon, resulting in a total of three 1x and six genotypes: e2, e3, e4.
, e4 is the primary risk structure in patients with advanced Alzheimer's disease (AD).
, e2 is the main common protective organism.
in the study, researchers used the National Alzheimer's Coordinating Center database to obtain data on 1,557 brain samples, including 130 e2 carriers and 679 e4 carriers, to explore their potential neuropulative effects by detecting the association of APOE e2 buildings with multiple neurodegenerative lesions.
APOE genotype associated with the relationship between amyloid and tau neuropathology AD-associated amyloid plaques and Braak graded pathology analyses showed that e2 carriers had a higher and more significant protective effect than e3/e3 and e4 carriers.
, the AD pathological risk of e2/e4 carriers is similar to that of e4 carriers, not e2 carriers.
analysis of multiple lesions in the frontal temporal lobe and tau protein lesions, there was no significant pathological correlation between e2 buildings.
relationship between the APOE e2/e4 genotype and Braak classification, the study showed that APOE e2 had a higher but restrictive protective effect on neurodegenerative diseases.
.
